SA519410292B1 - نظائر بنزو أزيبين كعوامل مثبِّطة لتيروسين كيناز لبروتون - Google Patents
نظائر بنزو أزيبين كعوامل مثبِّطة لتيروسين كيناز لبروتون Download PDFInfo
- Publication number
- SA519410292B1 SA519410292B1 SA519410292A SA519410292A SA519410292B1 SA 519410292 B1 SA519410292 B1 SA 519410292B1 SA 519410292 A SA519410292 A SA 519410292A SA 519410292 A SA519410292 A SA 519410292A SA 519410292 B1 SA519410292 B1 SA 519410292B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- benzo
- tetrahydro
- amino
- methyl
- butyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485745P | 2017-04-14 | 2017-04-14 | |
| PCT/US2018/027415 WO2018191577A1 (en) | 2017-04-14 | 2018-04-13 | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519410292B1 true SA519410292B1 (ar) | 2023-03-12 |
Family
ID=62092333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410292A SA519410292B1 (ar) | 2017-04-14 | 2019-10-10 | نظائر بنزو أزيبين كعوامل مثبِّطة لتيروسين كيناز لبروتون |
Country Status (36)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181109T1 (hr) | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| RS65386B1 (sr) | 2017-04-14 | 2024-04-30 | Biogen Ma Inc | Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze |
| US11820760B2 (en) | 2018-10-15 | 2023-11-21 | Biogen Ma Inc. | Crystalline polymorphs of Bruton's tyrosine kinase inhibitors |
| JP7747523B2 (ja) * | 2019-05-15 | 2025-10-01 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240216330A1 (en) * | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023086521A1 (en) | 2021-11-10 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
| CA3240051A1 (en) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| ES2406129T3 (es) | 2007-10-05 | 2013-06-05 | Verastem, Inc. | Derivados de purina sustituidos con pirimidina |
| JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI557127B (zh) * | 2009-09-04 | 2016-11-11 | 百健Ma公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| CN103889987B (zh) | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| HRP20181109T1 (hr) | 2013-12-11 | 2018-11-02 | Biogen Ma Inc. | Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| RS65386B1 (sr) | 2017-04-14 | 2024-04-30 | Biogen Ma Inc | Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze |
-
2018
- 2018-04-13 RS RS20240419A patent/RS65386B1/sr unknown
- 2018-04-13 EA EA201992354A patent/EA201992354A1/ru unknown
- 2018-04-13 CR CR20190517A patent/CR20190517A/es unknown
- 2018-04-13 SM SM20240166T patent/SMT202400166T1/it unknown
- 2018-04-13 TW TW111149550A patent/TWI846229B/zh active
- 2018-04-13 IL IL269933A patent/IL269933B/en unknown
- 2018-04-13 DK DK18721632.0T patent/DK3609886T3/da active
- 2018-04-13 SG SG11201909224Q patent/SG11201909224QA/en unknown
- 2018-04-13 FI FIEP18721632.0T patent/FI3609886T3/fi active
- 2018-04-13 CN CN202311088635.7A patent/CN117567453A/zh active Pending
- 2018-04-13 JP JP2019555961A patent/JP7145874B2/ja active Active
- 2018-04-13 AU AU2018253209A patent/AU2018253209B2/en active Active
- 2018-04-13 CA CA3058774A patent/CA3058774A1/en active Pending
- 2018-04-13 LT LTEPPCT/US2018/027415T patent/LT3609886T/lt unknown
- 2018-04-13 WO PCT/US2018/027415 patent/WO2018191577A1/en not_active Ceased
- 2018-04-13 KR KR1020257031163A patent/KR20250140646A/ko active Pending
- 2018-04-13 PE PE2024000228A patent/PE20240930A1/es unknown
- 2018-04-13 MA MA50013A patent/MA50013B1/fr unknown
- 2018-04-13 HR HRP20240361TT patent/HRP20240361T1/hr unknown
- 2018-04-13 AR ARP180100935A patent/AR111594A1/es not_active Application Discontinuation
- 2018-04-13 TW TW107112785A patent/TWI790227B/zh active
- 2018-04-13 UA UAA201911128A patent/UA127347C2/uk unknown
- 2018-04-13 US US15/952,505 patent/US10227341B2/en active Active
- 2018-04-13 PL PL18721632.0T patent/PL3609886T3/pl unknown
- 2018-04-13 IL IL316713A patent/IL316713A/en unknown
- 2018-04-13 EP EP23187919.8A patent/EP4249071A3/en active Pending
- 2018-04-13 PE PE2019002016A patent/PE20200740A1/es unknown
- 2018-04-13 CN CN201880031744.6A patent/CN110621670B/zh active Active
- 2018-04-13 HU HUE18721632A patent/HUE066253T2/hu unknown
- 2018-04-13 ES ES18721632T patent/ES2975769T3/es active Active
- 2018-04-13 JO JOJO/P/2019/0233A patent/JOP20190233B1/ar active
- 2018-04-13 EP EP18721632.0A patent/EP3609886B1/en active Active
- 2018-04-13 SI SI201831083T patent/SI3609886T1/sl unknown
- 2018-04-13 PT PT187216320T patent/PT3609886T/pt unknown
- 2018-04-13 KR KR1020237040706A patent/KR102862996B1/ko active Active
- 2018-04-13 MD MDE20200193T patent/MD3609886T2/ro unknown
- 2018-04-13 KR KR1020197032715A patent/KR102607900B1/ko active Active
- 2018-04-13 IL IL294175A patent/IL294175B2/en unknown
- 2018-08-27 US US16/113,455 patent/US10189829B2/en active Active
-
2019
- 2019-04-13 CR CR20230539A patent/CR20230539A/es unknown
- 2019-08-07 US US16/534,540 patent/US10961237B2/en active Active
- 2019-10-10 SA SA519410292A patent/SA519410292B1/ar unknown
- 2019-10-11 MX MX2023000812A patent/MX2023000812A/es unknown
- 2019-10-11 CL CL2019002900A patent/CL2019002900A1/es unknown
- 2019-10-14 PH PH12019502334A patent/PH12019502334A1/en unknown
- 2019-11-12 CO CONC2019/0012571A patent/CO2019012571A2/es unknown
-
2021
- 2021-02-24 US US17/183,702 patent/US11427577B2/en active Active
-
2022
- 2022-07-22 US US17/871,157 patent/US11858926B2/en active Active
- 2022-08-18 AU AU2022218560A patent/AU2022218560B2/en active Active
- 2022-09-20 JP JP2022148866A patent/JP7581294B2/ja active Active
-
2023
- 2023-06-12 ZA ZA2023/06172A patent/ZA202306172B/en unknown
- 2023-06-15 AR ARP230101541A patent/AR129632A2/es unknown
-
2024
- 2024-06-20 AU AU2024204241A patent/AU2024204241A1/en active Pending
- 2024-10-30 JP JP2024190472A patent/JP7778206B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022218560B2 (en) | Benzoazepine analogs as inhibiting agents for Bruton's tyrosine kinase | |
| SA518391342B1 (ar) | مركبات بنزولاكتام كمثبط بروتين كيناز | |
| RU2663898C2 (ru) | Пиразольные соединения в качестве модуляторов fshr и их применение | |
| US12565490B2 (en) | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | |
| UA121539C2 (uk) | Гетероцикліламіни як інгібітори рі3к | |
| BR112020019824A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente | |
| HUE028555T2 (en) | Pyrazolinquinoline Derivatives as PDE9 Inhibitors | |
| AU2020201240A1 (en) | Pyrazole compounds as modulators of FSHR and uses thereof | |
| EP3036238A1 (en) | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | |
| EA028599B1 (ru) | Пиразолилхиноксалиновые ингибиторы киназы | |
| CA3230071A1 (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| JP2023526839A (ja) | アゼチジン環状尿素類 | |
| AU2014302710A1 (en) | Imidazole compounds as modulators of FSHR and uses thereof | |
| WO2025264959A1 (en) | Substituted pyrazolopyridines as phosphoinosidide kinase (pik) modulators | |
| CA3172186A1 (en) | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 | |
| EA049687B1 (ru) | Азетидинцикломочевины | |
| EA040817B1 (ru) | Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона | |
| EA048315B1 (ru) | Ингибиторы fgfr и способы их применения | |
| SA516371288B1 (ar) | مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأورام، طب الأعصاب وعلم المناعة |